Filing Flows › Companies › Phibro Animal Health › Timeline
Phibro Animal Health stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−22.4% to $32.96
Phibro Animal Health (PAHC) stock fell 22% over the last 252 sessions, to $32.96. On the way it reported 4 quarters, its insiders filed 1 open-market trade and 3 Form 144 notices of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026 | Earnings | Earnings: beat the EPS estimate by 0.9% | +4.6% (+3.0% vs SPY) | — | — |
| Sep 16, 2026 | Form 144 | Form 144: BFI Co. LLC plans to sell $12.4M | +0.8% (+1.2% vs SPY) | +0.3% (−2.0% vs SPY) | +8.0% (+6.1% vs SPY) |
| Aug 26, 2026 | Earnings | Earnings: beat the EPS estimate by 17.1% | +0.4% (+0.4% vs SPY) | +6.6% (+7.1% vs SPY) | −5.4% (−5.8% vs SPY) |
| Aug 4, 2026 | Form 144 | Form 144: Jack Bendheim plans to sell $84K | −1.5% (−3.3% vs SPY) | −8.4% (−10.4% vs SPY) | +3.2% (+2.7% vs SPY) |
| Aug 4, 2026 | Form 144 | Form 144: Glenn David plans to sell $31K | −1.5% (−3.3% vs SPY) | −8.4% (−10.4% vs SPY) | +3.2% (+2.7% vs SPY) |
| Jun 26, 2026 | 8-K | Directors and officers: departures, appointments, pay | +0.4% (−1.3% vs SPY) | +7.4% (+4.4% vs SPY) | +13.8% (+12.2% vs SPY) |
| May 29, 2026 | Insider buy | Corcoran E Thomas bought $318K | −3.3% (−3.6% vs SPY) | +4.2% (+3.8% vs SPY) | +0.4% (+1.9% vs SPY) |
| May 6, 2026 | Earnings | Earnings: beat the EPS estimate by 6.5% | +3.9% (+2.6% vs SPY) | −43.0% (−45.0% vs SPY) | −52.8% (−57.3% vs SPY) |
| Apr 30, 2026 | 8-K | Material definitive agreement | +3.2% (+2.9% vs SPY) | −20.9% (−22.7% vs SPY) | −57.7% (−63.1% vs SPY) |
| Apr 14, 2026 | 8-K | Directors and officers: departures, appointments, pay | −7.0% (−7.8% vs SPY) | −8.7% (−10.1% vs SPY) | −51.5% (−58.2% vs SPY) |
| Feb 4, 2026 | Earnings | Earnings: beat the EPS estimate by 29.9% | −0.8% (−0.3% vs SPY) | +22.5% (+22.2% vs SPY) | +18.5% (+19.7% vs SPY) |
| Dec 18, 2025 | 8-K | Directors and officers: departures, appointments, pay | −8.1% (−9.0% vs SPY) | −5.7% (−8.0% vs SPY) | +3.7% (+2.1% vs SPY) |
Insiders’ record here
In the year on the chart, Phibro Animal Health's insiders reported 1 open-market buy ($318K) and 0 sales ($0). Of the 1 old enough to score, 1 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was +20.6% and after a sale —.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Phibro Animal Health: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.